Alpha Cognition Inc.
Alpha Cognition Inc.
Alpha Cognition Inc. is a pre-NDA, biopharmaceutical company dedicated to developing treatments for patients suffering from Alzheimer’s disease and ALS. ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition and inflammation. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia.
Alpha Cognition Inc. (ACOG)
SEDAR Information
Company Info
Capitalization
Company Officers
News Releases
Bulletins
2023-1003 - Expiry - Alpha Cognition Inc. - 1OCT2023 Warrants (ACOG.WT)
le 3 octobre/October 2023
Alpha Cognition Inc. - 1OCT2023 Warrants listed on May 1, 2023 expired on October 1, 2023.
Trading is currently halted.
The warrants will be delisted at market close October 3, 2023.
________________________
Alpha Cognition Inc. - 1OCT2023 Les bons de souscription cotés le 1er mai 2023 ont expiré le 1er octobre 2023.